|
Lessons learned from the metastatic castration-resistant prostate cancer phase I trial of EPI-506, a first-generation androgen receptor N-terminal domain inhibitor. |
|
|
No Relationships to Disclose |
|
|
Employment - Cleave Biosciences; ESSA |
Stock and Other Ownership Interests - Cleave Biosciences; ESSA |
Patents, Royalties, Other Intellectual Property - Cleave Biosciences; ESSA |
Travel, Accommodations, Expenses - Cleave Biosciences; ESSA |
|
|
Patents, Royalties, Other Intellectual Property - ESSA |
|
|
Stock and Other Ownership Interests - ESSA |
Patents, Royalties, Other Intellectual Property - ESSA |
|
|
Consulting or Advisory Role - ESSA |
Patents, Royalties, Other Intellectual Property - ESSA |
|
|
No Relationships to Disclose |
|
|
|
|
Stock and Other Ownership Interests - ESSA |
|
Patents, Royalties, Other Intellectual Property - ESSA |
Travel, Accommodations, Expenses - ESSA |
|
|
Stock and Other Ownership Interests - ESSA |
Consulting or Advisory Role - ESSA |
|
Patents, Royalties, Other Intellectual Property - ESSA |
|
|
|
Stock and Other Ownership Interests - ESSA |
Consulting or Advisory Role - ESSA |
|
Patents, Royalties, Other Intellectual Property - ESSA |
Expert Testimony - Pfizer |
Travel, Accommodations, Expenses - ESSA |
|
|
|
|
Stock and Other Ownership Interests - ESSA |
Research Funding - ESSA (Inst) |
Patents, Royalties, Other Intellectual Property - ESSA |
Travel, Accommodations, Expenses - ESSA |
|
|
Honoraria - Astellas Pharma; Bayer; Janssen; Sanofi |
Consulting or Advisory Role - Amgen; Astellas Pharma; Bayer; ESSA; Janssen; Lilly/ImClone; Sanofi |
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); Lilly/ImClone (Inst); Merck (Inst); Roche (Inst); Sanofi (Inst); Tokai Pharmaceuticals (Inst) |